Sickle cell anemia is caused by a single genetic mutation in the gene that produces hemoglobin, the protein red blood cells use to carry oxygen. That one tiny change, a swap of just one amino acid building block, triggers a chain reaction that distorts red blood cells, clogs blood vessels, and shortens cell lifespan from 120 days to as few as 10. An estimated 7.74 million people worldwide live with sickle cell disease, with sub-Saharan Africa accounting for nearly 80% of cases.
The Genetic Mutation Behind It
The root cause is a mutation in the HBB gene, located on chromosome 11. This gene carries the instructions for making beta-globin, one of the key components of hemoglobin. In sickle cell anemia, a single DNA letter is swapped: an A becomes a T. That one-letter change swaps the amino acid glutamic acid for valine at position 6 of the beta-globin protein. The result is an altered form of hemoglobin called hemoglobin S (HbS).
What makes this substitution so damaging is chemistry. Glutamic acid carries a negative electrical charge and sits comfortably on the surface of the hemoglobin molecule, interacting with the watery environment inside a red blood cell. Valine, by contrast, is hydrophobic. It repels water and instead sticks to neighboring hemoglobin molecules. That stickiness is what sets off everything that follows.
How One Amino Acid Deforms a Blood Cell
Inside healthy red blood cells, hemoglobin molecules float freely, picking up oxygen in the lungs and releasing it in the body’s tissues. In cells carrying hemoglobin S, problems begin at the moment of oxygen release. When HbS drops off its oxygen in the tissues, the exposed valine on one molecule latches onto a complementary pocket on a neighboring molecule. Those pairs attract more molecules, forming long, rigid fibers inside the cell.
This process, called polymerization, is extraordinarily sensitive to concentration. The rate at which fibers form depends on up to the 40th power of the HbS concentration inside the cell, meaning even small increases in the amount of abnormal hemoglobin dramatically accelerate fiber formation. Once enough fibers accumulate, they force the normally disc-shaped, flexible red blood cell into the stiff crescent or “sickle” shape that gives the disease its name.
The first fiber to form in a given cell requires a critical buildup of molecules before it becomes energetically favorable, which creates a characteristic delay. This delay is why sickling doesn’t happen instantly and why cells can sometimes return to a normal shape when they pick up oxygen again in the lungs. Over time, though, repeated cycles of sickling and unsickling damage the cell membrane permanently.
How Sickle Cell Is Inherited
Sickle cell anemia follows an autosomal recessive inheritance pattern, meaning a child must inherit a copy of the mutated HBB gene from each parent to develop the disease. When both parents carry one copy of the mutation (a condition called sickle cell trait), each pregnancy has these odds:
- 25% chance the child inherits two mutated copies and has sickle cell disease
- 50% chance the child inherits one mutated copy and carries sickle cell trait
- 25% chance the child inherits no mutated copies
People with sickle cell trait (one normal gene, one sickle gene) generally produce enough normal hemoglobin that their red blood cells function well under typical conditions. They can, however, pass the gene to their children.
Why the Trait Persists: The Malaria Connection
The sickle cell mutation is most common in populations from regions where malaria has historically been widespread, and that’s not a coincidence. Carrying one copy of the sickle gene provides significant protection against malaria, the parasitic disease spread by mosquitoes. This survival advantage has kept the gene circulating in these populations for thousands of years.
The protective mechanism works through an elegant bit of biology. The malaria parasite invades red blood cells and needs to digest hemoglobin to grow and reproduce. Infected red blood cells stick to the walls of small blood vessels, where oxygen levels are low. In a person with sickle cell trait, that low-oxygen environment triggers hemoglobin S to polymerize inside the infected cell. Research published in PNAS found that this polymerization physically blocks the parasite from digesting hemoglobin, stalling its growth at an early stage before it can replicate its DNA. The parasite essentially starves inside the very cell it invaded. This growth arrest was complete in low-oxygen conditions and directly linked to the presence of HbS polymers, visible under electron microscopy as distinct fiber lines inside the cells.
What Happens Inside Blood Vessels
The sickle shape itself is only part of the problem. The real damage comes from a cascade of events inside small blood vessels. Sickled red blood cells are stiff and sticky, and they cling to the inner lining of blood vessels. But they don’t act alone. White blood cells, platelets, and the blood vessel walls themselves become chronically inflamed and activated, creating a multi-cell pileup that narrows and eventually blocks blood flow.
A protein called P-selectin plays a central role in this process. It appears on the surface of both blood vessel walls and platelets, acting like molecular velcro that captures passing blood cells and encourages them to pile up. Activated platelets bind to white blood cells, forming clumps that add to the blockage. The result is a vaso-occlusive crisis: a painful episode caused by oxygen being cut off from tissues downstream of the blockage.
Making things worse, sickled red blood cells are fragile. They rupture easily, spilling free hemoglobin into the bloodstream. That escaped hemoglobin soaks up nitric oxide, a molecule the body uses to keep blood vessels relaxed and open. With less nitric oxide available, blood vessels constrict, further restricting flow. The free hemoglobin also interferes with a clotting factor called von Willebrand factor, causing it to accumulate and promote even more cell adhesion. This creates a self-reinforcing cycle: blocked vessels cause tissue damage, which triggers more inflammation, which promotes more blockages.
Why Anemia Develops
Healthy red blood cells live about 120 days before the body recycles them and produces replacements. Sickled red blood cells survive only 10 to 20 days. The bone marrow simply cannot produce new red blood cells fast enough to keep up with this rapid destruction, resulting in a chronic shortage of oxygen-carrying cells. That shortage is the anemia in sickle cell anemia, and it causes persistent fatigue, weakness, and pallor.
How It’s Detected
In the United States, sickle cell disease is identified through newborn screening, a standard set of tests performed shortly after birth. The primary test is hemoglobin electrophoresis, which separates the different types of hemoglobin in a blood sample using an electric current. Each hemoglobin type migrates at a different speed, producing a pattern that reveals whether a baby has normal hemoglobin A, fetal hemoglobin F (normal in newborns), or the abnormal hemoglobin S. A baby with sickle cell disease will show predominantly hemoglobin S, while a baby with sickle cell trait will show both hemoglobin A and hemoglobin S.
Gene Therapies Targeting the Root Cause
Because sickle cell anemia traces back to a single gene mutation, it has become one of the first diseases targeted by gene therapy. In December 2023, the FDA approved two gene therapies that address the genetic cause directly rather than managing symptoms.
The first, Casgevy, uses CRISPR gene-editing technology to modify a patient’s own blood stem cells. Rather than correcting the sickle mutation itself, it edits a different genetic switch to boost production of fetal hemoglobin, the type of hemoglobin babies produce before birth. Fetal hemoglobin doesn’t polymerize with hemoglobin S, so higher levels of it prevent red blood cells from sickling. The edited stem cells are transplanted back into the patient’s bone marrow, where they multiply and begin producing red blood cells with protective levels of fetal hemoglobin.
The second therapy, Lyfgenia, takes a different approach. It uses a viral delivery vehicle to insert a new gene into the patient’s blood stem cells. That gene produces a modified hemoglobin called HbAT87Q, which functions like normal adult hemoglobin and reduces the risk of sickling and blood vessel blockages. Both therapies require the patient’s existing bone marrow to be cleared first, making the process intensive, but they offer the possibility of a one-time treatment for a condition that previously required lifelong management.